<DOC>
	<DOCNO>NCT01982435</DOCNO>
	<brief_summary>The primary objective study ass ocular systemic adverse event ranibizumab ( Lucentis ) DME ( diabetic macular edema ) follow previous treatment intravitreal bevacizumab ( Avastin ) .</brief_summary>
	<brief_title>Safety Efficacy Ranibizumab Diabetic Macular Edema</brief_title>
	<detailed_description>This open-label , Phase I/II study intravitreally administer 0.3mg ranibizumab ( Lucentis ) subject DME ( diabetic macular edema ) previously treat intravitreal bevacizumab ( Avastin ) randomize comparative dosing strategy , monthly v `` treat-and-extend . '' Thirty patient total enrol study , 15 group . This study 1-year treatment period . The recruitment period occur 1 year total potential study duration 2 year .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Subjects eligible follow criterion meet : Ability provide write informed consent comply study assessment full duration study Age &gt; 18 year ETDRS bestcorrected visual acuity 20/25 20/320 study eye Willing , commit , able return ALL clinic visit complete study relate procedure At least 6 previous bevacizumab injection diabetic macular edema last 12 month study eye . At least 2 bevacizumab injection within 10 week recent bevacizumab injection within 6 week baseline study visit study eye . Persistent fovealinvolving diabetic macular edema base presence intraretinal and/or subretinal fluid SDOCT foveal center study entry study eye . Subjects meet follow criterion exclude study : Pregnancy ( positive pregnancy test ) lactation Premenopausal woman use adequate contraception . The following consider effective mean contraception : surgical sterilization use oral contraceptive , barrier contraception either condom diaphragm conjunction spermicidal gel , IUD ( intrauterine device ) , contraceptive hormone implant patch . Intravitreal steroid periocular steroid treatment within 3 month study entry study eye . Focal/grid laser photocoagulation treatment within 3 month study entry study eye . Panretinal photocoagulation treatment within 3 month study entry study eye . Prior vitrectomy study eye History retinal detachment study eye Prior trabeculectomy filtration surgery study eye Active intraocular inflammation either eye Active ocular periocular infection either eye Active scleritis episcleritis either eye History retinal vascular disease ( e.g. , retinal vein occlusion , retinal artery occlusion ) study eye . Coexistent retinal disease diabetic retinopathy ( e.g. , AMD ( age relate macular degeneration ) , inherit retinal disease ) study eye . Intraocular surgery within 3 month study entry study eye . History corneal transplant corneal dystrophy study eye . Significant medium opacity study eye may interfere visual acuity study eye . Participation subject clinical study within 3 month study entry . History allergy topical iodine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Macular Edema</keyword>
</DOC>